Newsroom-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

language

ENGLISH
繁體中文

ABOUT

About Acepodia

Management Team

Board of Directors

Advisors
TECHNOLOGY

Overview

ACC

γδ2 T Cells

AD2C
PIPELINE

ACC-γδ2 T

ACC-oNK
NEWSROOM

All News

Press Releases

Events & Presentations

Publications

Media
PARTNERSHIPS
CONTACT

Contact Us

Careers

Powerful, accessible cell therapies for patients with cancer.

We develop innovative, highly effective cell therapies for cancer that are broadly accessible for patients.

FIND US

Acepodia USA

1600 Harbor Bay Parkway, Suite 140,
Alameda, CA 94502,
USA

Acepodia Taiwan

12F., No. 508, Sec. 7, Zhongxiao E. Rd.,
Nangang Dist., Taipei City 115011,
Taiwan (R.O.C.).

Tel: +1 (415) 366 7822 Email: info@acepodiabio.com

Press Releases
Events & Presentations
Publications
Media
All News

March 162021

Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells

Endpoints News

Learn more
March 162021

Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates

GlobeNewswire

Learn more
February 122021

$2,000-Per-Dose Cell Therapy In The Clinic

BioProcess Online

Learn more
February 032021

A Novel Endogenous CD16-Expressing Natural Killer Cell for Cancer Immunotherapy

Biochemistry and Biophysics Reports, Vol. 26, July 2021, 100935
Zih-Fei Cheng, Hao-Kang Li, Hsiu-Ping Yang, Chia-Yun Lee, Sai-Wen Tang, Yan-Liang Lin, Shih-Chia Hsiao

Learn more
January 192021

Acepodia's Approach to ACC & CAR Scalability

The Business of Biotech podcast

Learn more
January 112021

Acepodia Features in Biopharma Executive Perspectives on 2021

BioSpace

Learn more
November 092020

Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

GlobeNewswire

Learn more
November 022020

Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

GlobeNewswire

Learn more
October 222020

Acepodia to Present at the 7th Annual China Healthcare Summit

GlobeNewswire

Learn more
September 242020

Treating your first human with a cancer drug

TechNation Radio Podcast

Learn more
September 172020

ACE1702: A potent and off-the-shelf oNK cell therapy product

Cancer Research, 2020, 80:2169
Hao-Kang H. Li, Tai-Sheng E. Wu, Ching-Wen S. Hsiao, Sen-Han S. Yang, Chia-Yun S. Lee, Yan-Liang J. Lin, Zih-Fei Z. Cheng, Yu-Bei Cheng, Yan-Da D. Lai, Hsiu-Ping C. Yang, Sai-Wen S. Tang, Wei-Lun S. Lo, Janet Pan and Shih-Chia S. Hsiao

Learn more
September 142020

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell therapies

Fierce Biotech

Learn more

1 2 3 4 5 6

Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells

Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates

$2,000-Per-Dose Cell Therapy In The Clinic

A Novel Endogenous CD16-Expressing Natural Killer Cell for Cancer Immunotherapy

Acepodia's Approach to ACC & CAR Scalability

Acepodia Features in Biopharma Executive Perspectives on 2021

Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

Acepodia to Present at the 7th Annual China Healthcare Summit

Treating your first human with a cancer drug

ACE1702: A potent and off-the-shelf oNK cell therapy product

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell therapies